At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 53 enrolled
Drug / intervention
MM120 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Efficacy of Repeated Low Dose d-Lysergic Acid Diethylamide (LSD) D-tartrate (MM120) as Treatment for ADHD in Adults: a Multi-center, Randomized, Double-blind, Placebo-controlled Phase 2a Proof of Concept Trial
In Brief
A Phase 2 clinical trial evaluating MM120 and Placebo for ADHD and Attention Deficit Disorder. Completed, enrolled 53 participants across 2 sites in 2 countries.
Detailed Summary
This study measures the safety and efficacy of repeated low dose MM120 as treatment for ADHD in adults: a multi-center, randomized, double-blind, placebo-controlled
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsADHD, Attention Deficit Disorder
CountriesNetherlands, Switzerland
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
Enrollment StartDec 2021
First PostedJan 2022
Primary CompletionNov 2023
Study CompletionDec 2023
TodayJul 2026
First PostedJan 21, 2022
Enrollment StartDec 17, 2021
Primary CompletionNov 6, 2023
Study CompletionDec 4, 2023
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 4.4 years ago
Interventions
MM120drug
MM120 is a psychedelic drug that can cause intensified thoughts, emotions, and sensory perception. At sufficiently high dosages MM120 manifests primarily visual, as well as auditory, hallucinations.
Placeboother
A treatment which is designed to have no therapeutic value.